Eversense 365 Could Change the CGM Game ... If Senseonics Doesn't Fumble the ExecutionEversense 365 Could Change the CGM Game ... If Senseonics Doesn't Fumble the Execution

The advantages of a 365-day CGM are numerous, but commercial execution will be key for Senseonics.

Amanda Pedersen

October 30, 2024

4 Min Read
product image of an Eversense 365 CGM sensor and a smartphone displaying the accompanying app.
Senseonics' Eversense 365 is a fully-implantable, long-term continuous glucose monitoring (CGM) option that is highly-differentiated from short-term CGMs.

At a Glance

  • Senseonics' long-duration continuous glucose monitor requires only weekly calibration, sparking increased patient interest.
  • One medtech analyst sees strong potential for adoption but emphasizes the importance of successful commercial execution.

On the heels of winning FDA clearance for the world's first 365-day continuous glucose monitor (CGM), Senseonics recently hosted an investor call with key opinion leaders touting the benefits of the Eversense 365. The Germantown, MD-based company's CGM previously was cleared for 180 days.

"We came away from the event with increased optimism on the potential to accelerate patient adoption with this latest product cycle," Marie Thibault, a medtech analyst at BTIG, wrote in a report following the event. "With several novel commercial initiatives also in place... [Senseonics] will now need to show it can execute."

Senseonics also reported that Mercy, a large U.S. health system with 50 hospitals and 1,000 clinics across the Midwest, plans to implement a remote patient monitoring (RPM) program later this year that will allow clinicians to monitor patients' glucose levels between office visits, enabling timely interventions, personalized care adjustments, and the opportunity to prevent avoidable costly emergency room visits.

"This groundbreaking collaboration with Senseonics marks a milestone not just for our organization but for diabetes care globally," said Jeff Ciaramita, MD, with Mercy Health. "As with all chronic conditions such as congestive heart failure, chronic kidney disease, and diabetes, access to real-time actionable data is imperative to actually improving medical outcomes. These outcomes include overall long-term diabetes control but also immediate benefits such as keeping patients out of the emergency room."

Related:Senseonics Wins FDA Clearance for Year-Long CGM

In her report, Thibault noted that BTIG's rating for Senseonics is neutral and that, based on forecasted 2024 and 2025 revenue, shares are trading above the top-performing diabetes tech companies on an enterprise value-to-sales basis.

"We acknowledge the large market opportunity for the Eversense platform, but do not think a premium valuation multiple is warranted given the company’s past challenges in commercializing the product and the remaining risks related to commercial execution with its partner.

Why Eversense 365 makes 'sense' for diabetes management

The doctors on the call were clear advocates for the Eversense 365 CGM and its benefits compared to existing shorter-term CGMs. Below are some of the key points they each made, beginning with David Ahn, MD, with Hoag Medical Group:

  • Removable and long-lasting sensor: The Eversense 365 offers a unique removable sensor that lasts a full year, compared to the 7-15 day lifespan of traditional transcutaneous sensors. This flexibility allows users to remove the CGM when needed, making it appealing to those who may feel self-conscious about wearing a CGM continuously or need the option for specific activities, like swimming or mixed martial arts.

  • Vibratory alerts without a phone: Eversense 365 includes vibratory alerts from the transmitter, allowing users to monitor glucose levels even without a phone. This feature is beneficial in scenarios where phone use may be impractical or restricted, such as during presentations or outdoor activities.

  • Adhesive sensitivity advantage: Eversense 365 addresses adhesive allergy issues common with other CGMs. Its gentler adhesive can be changed multiple times a day, offering a solution for patients with sensitivities, which is particularly relevant for those with autoimmune conditions like type 1 diabetes.

  • High accuracy and no "compression lows": The Eversense 365 is known for its accuracy in detecting low blood sugar, a critical feature for diabetic patients, particularly those susceptible to hypoglycemia. Unlike other CGMs, it doesn’t suffer from "compression lows" caused by pressure artifacts during sleep, making it a more reliable option and less likely to wake the patient (and their sleeping partner) with a false alarm.

  • Simplified supply management and integration potential: With Eversense 365, users only need annual sensor replacements, minimizing the frequency of dealing with insurance and supply issues. The device’s anticipated integration with automated insulin delivery systems could further enhance glucose management options, particularly for patients who struggle with the limitations of other CGMs.

  • Weekly calibration: Some patients showed initial interest in Eversense, but Ahn said many were deterred by daily calibrations in the past. The weekly calibration feature of the 365 version has renewed interest among patients who previously passed on CGMs. The demand is expected to grow further once Eversense integrates with automated insulin delivery systems.

Ciaramita also highlighted multiple key advantages of the Eversense 365, such as:

  • Better compliance: Mercy has around 30,000 patients on insulin who could benefit from CGM. Despite awareness and reimbursement availability, barriers like acquisition complexity and device limitations have hindered adoption, according to Ciaramita. Eversense’s year-long sensor with fewer replacements and high accuracy is expected to address these challenges and boost compliance.

  • Population health Impact and cost reduction: By providing consistent glucose data, Eversense is expected to reduce diabetes-related hospitalizations and ER visits, aligning with Mercy’s value-based care focus. Continuous monitoring helps prevent complications, ultimately cutting long-term healthcare costs and improving patient outcomes, Ciaramita said.

  • Potential for scalable diabetes care model: Mercy aims to set a new standard in diabetes care management. Their scalable approach, including the RPM program, could serve as a model for other health systems, encouraging wider adoption and collaboration to improve diabetes care on a national level.

About the Author

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like